EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Quality of life in allergic rhinitis patients treated with intralymphatic immunotherapy (ILIT): A 19-year follow-up

Yasmin K Adlany, Lara Šošić, Gabriela Senti, Claudia C V Lang, Brunello Wüthrich, Thomas M Kündig, Pål Johansen

Journal of Allergy and Clinical Immunology: Global · 2023-02 · 2 (1) · 43-50

DOI: 10.1016/j.jacig.2022.09.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology: Global, 2023-02. Verfasst von Yasmin K Adlany und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Zurich, Raemistrasse 100, Zurich, Switzerland. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Universitätsspital Zürich, Allergy Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In 2002-2005, we conducted a phase I/II clinical trial where a new allergy immunotherapy (AIT) route was introduced: intralymphatic immunotherapy (ILIT). Ultrasound guidance allowed injection of allergen directly into inguinal lymph nodes. Grass pollen-allergic patients received 3 injections with 1-month intervals. The short ILIT was more patient-friendly, required lower dosing, and was comparable with SCIT regarding short-term efficacy, which was used as a reference.

Objective

Nineteen years after ILIT, the same patients were followed up to assess the long-term effect on quality of life and efficacy of the treatment.

Methods

Patients who received ILIT and SCIT in 2002-2005 and an additional group of patients, who completed SCIT in 2015-2018, were recruited. All participants received a trial-specific in-house questionnaire and a standardized Rhinoconjunctivitis Quality of Life Questionnaire. Data were recorded off- (February 2021) and on- (May-June 2021) season. Descriptive statistics were applied.

Results

Of 58 and 54 patients who originally received ILIT or SCIT, 25 (43%) and 29 (54%) patients, respectively, returned the questionnaires for analysis. Four (16%) and 3 (11%) of the ILIT and SCIT patients, respectively, developed complete protection against grass pollen-mediated rhinitis, whereas another 15 (60%) and 20 (69%) expressed satisfaction with the received AIT. In both groups, any persistent symptoms were reported as mild. Medication usage in the ILIT and SCIT groups was comparable. Nineteen (76%) and 23 (79%) patients, respectively, expressed satisfaction with their AIT.

Conclusions

Grass pollen ILIT leads to long-term significant improvement in rhinitis-associated quality of life 19 years after treatment, and the ILIT quality-of-life effect was not inferior to that of SCIT.

Schlagwörter

Stichwörter der Autor:innen

Allergen immunotherapyRQLQ(S)intralymphatic immunotherapyquality of liferhinoconjunctivitssymptom scores

Autor:innen und Institutionen

  • Department of Dermatology, University of Zurich, Raemistrasse 100, Zurich, Switzerland.
  • University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland.
  • Department of Dermatology, University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland.

Förderung

  • Universitätsspital Zürich
  • Allergy Therapeutics

Zitieren

APA

Adlany, Y. K., Šošić, L., Senti, G., Lang, C. C. V., Wüthrich, B., Kündig, T. M., & Johansen, P. (2023). Quality of life in allergic rhinitis patients treated with intralymphatic immunotherapy (ILIT): A 19-year follow-up. Journal of Allergy and Clinical Immunology: Global, 2(1), 43-50. https://doi.org/10.1016/j.jacig.2022.09.007

Vancouver

Adlany YK, Šošić L, Senti G, Lang CCV, Wüthrich B, Kündig TM, et al. Quality of life in allergic rhinitis patients treated with intralymphatic immunotherapy (ILIT): A 19-year follow-up. Journal of Allergy and Clinical Immunology: Global. 2023;2(1):43-50. doi:10.1016/j.jacig.2022.09.007

BibTeX
@article{Adlany2023,
  author = {Adlany, Yasmin K and Šošić, Lara and Senti, Gabriela and Lang, Claudia C V and Wüthrich, Brunello and Kündig, Thomas M and Johansen, Pål},
  title = {Quality of life in allergic rhinitis patients treated with intralymphatic immunotherapy (ILIT): A 19-year follow-up},
  journal = {Journal of Allergy and Clinical Immunology: Global},
  year = {2023},
  volume = {2},
  number = {1},
  pages = {43--50},
  doi = {10.1016/j.jacig.2022.09.007}
}
Kostenlos starten →